US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Stage

0.3754

+0.0000

Volume:- -

Turnover:- -

Market Cap:10.85M

PE:-0.11

High:0.3754

Open:0.3754

Low:0.3754

Close:0.3754

Loading ...

Overview Company News Filings

Ripple to Retain $75 Million From SEC As the XRP Lawsuit Enters Final Stage

Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts

Can-Fite BioPharma Begins Late-Stage Study of Prospective Psoriasis Medication

MT Newswires Live

Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting

Nanoveu Says US Patent for AI Technology Licensed to Emass Unit Still in Application Stage; Shares Drop 8%

MT Newswires Live

Press Release: IQST - IQSTEL Sets Stage for Explosive Growth: Signs MOU to Acquire Majority Stake in Fintech Leader GlobeTopper, Driving Fintech Expansion and Strengthening Revenue Outlook

Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment

IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer

Redfin Reports Near-Record Housing Costs Put a Lid on Pending Sales, Even as Early-Stage Demand Picks Up

Hold Rating on Pliant Therapeutics Amid Uncertainty and Limited Data from Early-Stage Trials

Cheniere Energy (NYSE:LNG) Marks Milestone With Completion Of Train 1 At Corpus Christi Stage 3

Simply Wall St.

Jensen Huang Takes Center Stage: What to Expect from Nvidia’s Big GTC 2025 Keynote

AZN's Imfinzi Gets EU Nod for Limited-Stage Small-Cell Lung Cancer

Cheniere Announces Substantial Completion of Train 1 at the Corpus Christi Stage 3 Project

Commentary: A stronger sports system is taking shape in Singapore, but the hard work is not over

Hong Kong’s Fintech Ecosystem Expands as Blockchain, AI, and Digital Assets Take Center Stage

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SSI/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SSI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SSI\",,,,,undefined,":{"symbol":"SSI","market":"US","secType":"STK","nameCN":"Stage","latestPrice":0.3754,"timestamp":1588968000000,"preClose":0.3754,"halted":3,"volume":0,"delay":0,"floatShares":20307519,"shares":28911336,"eps":-3.332056,"marketStatus":"Halted","change":0,"latestTime":"05-08 16:00:00 EDT","open":0.3754,"high":0.3754,"low":0.3754,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.332056,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743408000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":998884800000,"exchange":"NYSE","adjPreClose":0.3754,"dividendRate":0.133191,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SSI\",,,,,undefined,":{"symbol":"SSI","floatShares":20307519,"roa":"-3.54%","roe":"-44.60%","lyrEps":-3.1264,"shares":28911336,"dividePrice":0.05,"high":0.3754,"amplitude":0,"preClose":0.3754,"low":0.3754,"week52Low":0.27,"pbRate":"0.07","week52High":9.5,"institutionHeld":0.5253,"latestPrice":0.3754,"eps":-3.332056,"divideRate":0.133191,"volume":0,"delay":0,"ttmEps":-3.332056,"open":0.3754,"prevYearClose":8.12},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SSI\",pageSize:16,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522833781","title":"Ripple to Retain $75 Million From SEC As the XRP Lawsuit Enters Final Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=2522833781","media":"BE[IN]CRYPTO","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522833781?lang=en_us&edition=fundamental","pubTime":"2025-03-26 04:03","pubTimestamp":1742933003,"startTime":"0","endTime":"0","summary":"Ripple now has the ability to sell XRP tokens to institutional investors, potentially boosting liquidity and partnerships.Despite the legal win, XRP's price has remained stagnant, likely impacted by broader bearish market trends.Ripple’s Chief Legal Officer announced today that its XRP lawsuit with the SEC is approaching the final legal phase. The SEC will keep $50 million from the previous $125 million fine and return the rest to Ripple.Most importantly, Ripple will likely be able to offer XRP tokens to institutional investors, which could impact market liquidity and ETF approval odds.Another critical ruling in the 2024 decision was that Ripple could not sell XRP to institutional investors. The firm had reportedly been negotiating with the SEC to drop this mandate for weeks.Over the past week, the XRP community has expressed some concerns regarding the extremely low DEX trading volume on the network. Yet, Ripple’s new progress with the SEC may create plenty of opportunities to foster ","market":"nz","thumbnail":"https://beincrypto.com/wp-content/uploads/2023/06/BIC_Ripple-covers-850x478.png","type":0,"news_type":0,"thumbnails":["https://beincrypto.com/wp-content/uploads/2023/06/BIC_Ripple-covers-850x478.png"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://beincrypto.com/sec-return-fine-in-ripple-xrp-lawsuit/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"beincrypto_highlight","symbols":["SSI","XRP.USD.CC"],"gpt_icon":0},{"id":"2522670794","title":"Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2522670794","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522670794?lang=en_us&edition=fundamental","pubTime":"2025-03-25 04:05","pubTimestamp":1742846700,"startTime":"0","endTime":"0","summary":"Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 millionGraftAssure RUO assay launched July 2024Signed strategic partner and investor, Bio-Rad LaboratoriesFully funded cli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/24/3048296/0/en/Oncocyte-Reports-Successful-2024-Sets-Stage-for-2025-Catalysts.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2463526074.USD","BK4136","LU1169590202.USD","NPV","LU1169589451.USD","NGS","BK4121","AMR","BK4585","LU1481599808.USD","IP","BK4588","BK4179","LU1481600234.SGD","LU1487256676.USD","SSI","BIO","BK4006"],"gpt_icon":0},{"id":"2521277627","title":"Can-Fite BioPharma Begins Late-Stage Study of Prospective Psoriasis Medication","url":"https://stock-news.laohu8.com/highlight/detail?id=2521277627","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521277627?lang=en_us&edition=fundamental","pubTime":"2025-03-24 22:08","pubTimestamp":1742825324,"startTime":"0","endTime":"0","summary":"Can-Fite BioPharma  said Monday it has initiated a phase 3 study of its Piclidenoson drug candidate in patients with moderate to severe plaque psoriasis, with enrollment starting in Europe and in the US with Canada to follow.The co-primary objectives of the study are the proportion of patients whose psoriasis is reduced in size and severity by 75% or more and the proportion who achieve a Static Physician's Global Assessment score of either 0 or 1 after 16 weeks, the company said.The US Food and Drug Administration encouraged the company to enroll adolescent patients due to the strong safety profile of the drug  demonstrated during development and earlier trials, Can-Fite said.Can-Fite is expecting to file a new drug application for Piclidenoson with the FDA and a marketing authorization plan with the European Medicines Agency on the successful conclusion of the trial, the company said.Price: 1.66, Change: +0.06, Percent Change: +3.94","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SSI","CANF","BK4139"],"gpt_icon":0},{"id":"2521474177","title":"Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2521474177","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521474177?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:00","pubTimestamp":1742817600,"startTime":"0","endTime":"0","summary":"BOSTON, March  24, 2025  (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/24/3047808/0/en/Praxis-Precision-Medicines-to-Present-on-Late-Stage-Programs-across-Epilepsy-and-Movement-Disorders-at-the-American-Academy-of-Neurology-2025-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SSI","AFG","MDCO","PRAX"],"gpt_icon":0},{"id":"2521528317","title":"Nanoveu Says US Patent for AI Technology Licensed to Emass Unit Still in Application Stage; Shares Drop 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2521528317","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521528317?lang=en_us&edition=fundamental","pubTime":"2025-03-24 13:01","pubTimestamp":1742792509,"startTime":"0","endTime":"0","summary":"Nanoveu  corrected its Dec. 12, 2024, statement to clarify that the US patent for an artificial intelligence-based vision technology exclusively licensed to its Emass subsidiary is still in the application stage, according to a March 21 filing with the Australian bourse.The patent was published on Sept. 5, 2024, and the current status is \"pending,\" the company said in the filing. The application was filed on March 1, 2024.The company's shares dropped 8% in recent Monday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","BK7076","NVU.AU","SSI"],"gpt_icon":0},{"id":"2521286450","title":"Press Release: IQST - IQSTEL Sets Stage for Explosive Growth: Signs MOU to Acquire Majority Stake in Fintech Leader GlobeTopper, Driving Fintech Expansion and Strengthening Revenue Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2521286450","media":"Dow Jones","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521286450?lang=en_us&edition=fundamental","pubTime":"2025-03-21 20:45","pubTimestamp":1742561100,"startTime":"0","endTime":"0","summary":"IQST - IQSTEL Sets Stage for Explosive Growth: Signs MOU to Acquire Majority Stake in Fintech Leader GlobeTopper, Driving Fintech Expansion and Strengthening Revenue Outlook. NEW YORK, March 21, 2025 /PRNewswire/ -- IQSTEL Inc. , the fast-growing multinational provider of Telecom, Fintech, Cybersecurity, and AI-driven services, is excited to announce the signing of a Memorandum of Understanding  to acquire a 51% equity interest in GlobeTopper, LLC , a cutting-edge fintech company revolutionizing B2B Top-Up solutions.This strategic acquisition marks another key milestone in IQSTEL's aggressive growth trajectory, reinforcing its Fintech division while setting the stage for long-term, high-margin revenue growth.A Brilliant Future Ahead: Accelerating Toward $1 Billion Milestone. Following its record-breaking $283 million revenue in FY-2024, iQSTEL has confidently forecasted $340 million in revenue for 2025, primarily driven by its robust Telecom Division. The acquisition of GlobeTopper is ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IQST","SSI","FTVI"],"gpt_icon":0},{"id":"2521493824","title":"Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2521493824","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521493824?lang=en_us&edition=fundamental","pubTime":"2025-03-21 02:26","pubTimestamp":1742495195,"startTime":"0","endTime":"0","summary":"On Thursday, Aptevo Therapeutics  announced two additional frontline Acute Myeloid Leukemia  patients have achieved remission within 30 days of treatment in the RAINIER dose optimization trial of mipletamig in combination with standard of care for patients unfit for intensive chemotherapy.9 of 10 frontline patients across two trials achieved remission when receiving the triplet combination of mipletamig + venetoclax + azacitidine .Notably, no cytokine release syndrome  has been reported in the RAINIER trial to date.Together with the addition of these interim Cohort 2 results, mipletamig has achieved a compelling overall remission rate of 90% among frontline patients, outperforming the doublet remission rate from a venetoclax + azacitidine-only study of 66%.In December 2024, Aptevo Therapeutics announced that 100% of patients achieved remission within 30 days in Cohort 1 of the RAINIER frontline acute myeloid leukemia  Phase 1b trial, including two patients who experienced complete remi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aptevo-therapeutics-says-two-additional-182635823.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4006","IE00B7SZL793.SGD","APVO","IE00B66KJ199.SGD","LU2065731478.USD","SSI","BK4161","IE00B19Z4B17.USD","BK4139","CRS","CR","IE0031619046.USD"],"gpt_icon":0},{"id":"2520456768","title":"IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2520456768","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520456768?lang=en_us&edition=fundamental","pubTime":"2025-03-20 20:30","pubTimestamp":1742473800,"startTime":"0","endTime":"0","summary":"IceCure working in close collaboration with FDA towards De Novo decision. CAESAREA, Israel, March 20, 2025 /PRNewswire/ -- IceCure Medical Ltd.  , developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it is in continued discussions with the U.S. Food and Drug Administration  regarding its De Novo marketing authorization request for ProSense in early-stage low risk breast cancer with endocrine therapy. The Company now expects the FDA's marketing authorization decision to be reached after the first quarter of 2025.Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the \"safe harbor\" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as \"expects,\" \"anticipates,\" \"intends,\" \"plans,\" \"believes,\" \"seeks,\" \"estimates\" and similar expressions or variations of such words are intended to id","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/icecure-reports-updated-timeline-progress-123000122.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/icecure-reports-updated-timeline-progress-123000122.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SSI","BK4082","PRGS","BK4097","LU2065732104.USD","ICCM"],"gpt_icon":0},{"id":"2520345504","title":"Redfin Reports Near-Record Housing Costs Put a Lid on Pending Sales, Even as Early-Stage Demand Picks Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2520345504","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520345504?lang=en_us&edition=fundamental","pubTime":"2025-03-20 20:00","pubTimestamp":1742472000,"startTime":"0","endTime":"0","summary":"House hunters are touring homes and applying for mortgages as rates stay below 7%, but prospective buyers aren’t always following through with a purchase. SEATTLE, March 20, 2025---- —The typical U.S. homebuyer’s monthly housing payment is $2,793, just a few dollars shy of the all-time high, according to a new report from Redfin , the technology-powered real estate brokerage. Housing payments are sky-high because sale prices keep rising and mortgage rates remain high.The median home-sale price rose 3.3% year over year during the four weeks ending March 16, and the weekly average mortgage rate is 6.65%, its lowest level since mid-December but still more than double pandemic-era lows.Lack of affordability is suppressing homebuyer demand, even as we get tantalizingly close to spring. Pending home sales are down 5.2%, on par with the annual declines Redfin has seen for the last two months.Up from 6.7% two weeks earlier, but still near lowest level since December","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/redfin-reports-near-record-housing-120000447.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RDFN","SSI"],"gpt_icon":0},{"id":"2520745929","title":"Hold Rating on Pliant Therapeutics Amid Uncertainty and Limited Data from Early-Stage Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2520745929","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520745929?lang=en_us&edition=fundamental","pubTime":"2025-03-19 15:56","pubTimestamp":1742371013,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Faisal Khurshid has reiterated their neutral stance on PLRX stock, giving a Hold rating yesterday. Faisal Khurshid’s ratin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/hold-rating-on-pliant-therapeutics-amid-uncertainty-and-limited-data-from-early-stage-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/hold-rating-on-pliant-therapeutics-amid-uncertainty-and-limited-data-from-early-stage-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","SSI"],"gpt_icon":0},{"id":"2520933554","title":"Cheniere Energy (NYSE:LNG) Marks Milestone With Completion Of Train 1 At Corpus Christi Stage 3","url":"https://stock-news.laohu8.com/highlight/detail?id=2520933554","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520933554?lang=en_us&edition=fundamental","pubTime":"2025-03-19 01:56","pubTimestamp":1742320585,"startTime":"0","endTime":"0","summary":"Cheniere Energy recently marked the substantial completion of Train 1 at its Corpus Christi Stage 3 Liquefaction Project, a development that may impact its operations and potentially its stock performance. This milestone adds to Cheniere's growing LNG capacity and aligns with its strategic expansion goals. Despite this positive development, the company's 5.62% price increase over the last quarter comes amid a broader market downturn, with indices like the Dow Jones and S&P 500 experiencing declines. Cheniere's performance contrasts with the overall negative sentiment in the market, possibly due to its product-related announcements that emphasized growth and completion timelines. Additionally, the company reported lower financial metrics, including revenue and earnings, which did not appear to affect its stock adversely during this period. This resilience and focus on completing key projects like Train 1 may have helped sustain investor confidence and contributed to its share price incr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cheniere-energy-nyse-lng-marks-175625633.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B29SXL02.USD","SSI","LU0630314457.HKD","LU0788109394.HKD","LU0345770308.USD","LU0345780950.USD","LU0368265418.SGD","LU0345770993.USD","LU0170899867.USD","LU0742534661.SGD","LNG","LU0314104364.USD","LU0251131958.USD","NYSE","LU0251142724.SGD","LU0048573561.USD","LU2449327464.USD","BK4144","IE00B29SXK94.USD","LU0345781412.USD","LU0122376428.USD"],"gpt_icon":0},{"id":"2520178640","title":"Jensen Huang Takes Center Stage: What to Expect from Nvidia’s Big GTC 2025 Keynote","url":"https://stock-news.laohu8.com/highlight/detail?id=2520178640","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520178640?lang=en_us&edition=fundamental","pubTime":"2025-03-18 18:35","pubTimestamp":1742294112,"startTime":"0","endTime":"0","summary":"NVIDIA’s ($NVDA) GTC 2025 is here and is one of the year’s biggest tech events. Running from March 17-21, this four-day conference is all about the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/jensen-huang-takes-center-stage-what-to-expect-from-nvidias-big-gtc-2025-keynote?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/jensen-huang-takes-center-stage-what-to-expect-from-nvidias-big-gtc-2025-keynote?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI","IE00BJTD4V19.USD","LU2756315664.SGD","NVD2.UK","LU1674673428.USD","LU1244550577.SGD","NVDS.UK","2NVD.UK","LU1868836591.USD","LU2087621335.USD","NVDU","LU0943347566.SGD","LU0353189680.USD","IE00B19Z8W00.USD","LU0107464264.USD","NVDA","SG9999015952.SGD","LU0868494617.USD","LU1935043023.USD","LU0077335932.USD","LU1629891620.HKD","NVD","NVD3.UK","LU0175139822.USD","LU2750360997.AUD","LU2097344431.USD","NVDD","LU1989764748.USD","LU0965509283.SGD","LU1861127337.USD","SG9999015358.SGD","NVDY","IE0034235295.USD","SNVD.UK","LU1720051017.SGD","LU1989764664.SGD","LU0234570918.USD","LU1064131342.USD","IE00BKVL7J92.USD","NVIW.SI","LU2417539215.USD","LU2168564065.EUR","GB00BDT5M118.USD","3NVD.UK","NVDS","LU0823434740.USD","LU2125909916.SGD","LU1548497426.USD"],"gpt_icon":0},{"id":"2520570285","title":"AZN's Imfinzi Gets EU Nod for Limited-Stage Small-Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2520570285","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520570285?lang=en_us&edition=fundamental","pubTime":"2025-03-17 23:10","pubTimestamp":1742224200,"startTime":"0","endTime":"0","summary":"AstraZeneca AZN recently announced that the European Commission has approved its blockbuster cancer drug Imfinzi  as monotherapy for treating limited-stage small cell lung cancer  in adult patients whose disease has not progressed following platinum-based chemoradiation therapy .The latest approval for Imfinzi in the European Union  was based on data from the phase III ADRIATIC study.Data from the phase III ADRIATIC study showed that treatment with Imfinzi reduced the risk of death by 27% as compared to placebo. Additionally, treatment with Imfinzi reduced the risk of disease progression or death by 24% versus placebo.The approval in the EU was expected as the Committee for Medicinal Products for Human Use recommended approval of Imfinzi as monotherapy for treating LS-SCLC in adult patients whose disease has not progressed following platinum-based CRT in February 2025.The FDA approved Imfinzi for a similar indication in December 2024.Hypoparathyroidism patients suffer from a deficiency","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/azns-imfinzi-gets-eu-nod-151000804.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BMRN","CRT","LU2456880835.USD","LU2417539215.USD","LU0320765992.SGD","ARVN","BK4213","BK4588","LU0889565916.HKD","BK4566","BK4585","SSI","LU1829250122.USD","BK4007","BK4156","BK4568","LU0109394709.USD","IE00B19Z3B42.SGD","DVAX","LU2462157665.USD","IE0002270589.USD","IE00B19Z3581.USD","LU2236285917.USD","IE00B7SZLL34.SGD","BK4139","AZN"],"gpt_icon":0},{"id":"2520081527","title":"Cheniere Announces Substantial Completion of Train 1 at the Corpus Christi Stage 3 Project","url":"https://stock-news.laohu8.com/highlight/detail?id=2520081527","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520081527?lang=en_us&edition=fundamental","pubTime":"2025-03-17 20:30","pubTimestamp":1742214600,"startTime":"0","endTime":"0","summary":"HOUSTON, March 17, 2025----Cheniere Energy, Inc.   today announced that Substantial Completion of Train 1 at the Corpus Christi Stage 3 Liquefaction Project  was achieved on March 16, 2025. Commissioning is complete and Cheniere’s engineering, procurement and construction partner, Bechtel Energy, Inc.  has turned over care, custody, and control of Train 1 and associated systems to Cheniere. With the achievement of Substantial Completion, financial results from liquefied natural gas  sales from Train 1 going forward will be reflected in the statement of operations of Cheniere and its applicable affiliates.\"The substantial completion of the first train of CCL Stage 3 - ahead of schedule and on budget - marks another important milestone for Cheniere and further builds upon the track record of excellence in execution consistently delivered by the Cheniere and Bechtel teams,\" said Jack Fusco, Cheniere’s President and Chief Executive Officer. \"We remain focused on safely and efficiently brin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cheniere-announces-substantial-completion-train-123000516.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B29SXL02.USD","LU0788109394.HKD","LU0048573561.USD","LU0251131958.USD","LU0345770308.USD","LU0345780950.USD","CCL","BK4144","LNG","BK4585","BK4517","BK4588","LU0368265418.SGD","LU0170899867.USD","LU2449327464.USD","LU0314104364.USD","SSI","LU0345781412.USD","BK4547","LU0122376428.USD","LU0742534661.SGD","LU0630314457.HKD","LU0345770993.USD","BK4142","IE00B29SXK94.USD","LU0251142724.SGD"],"gpt_icon":0},{"id":"2520629095","title":"Commentary: A stronger sports system is taking shape in Singapore, but the hard work is not over","url":"https://stock-news.laohu8.com/highlight/detail?id=2520629095","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520629095?lang=en_us&edition=fundamental","pubTime":"2025-03-17 06:00","pubTimestamp":1742162400,"startTime":"0","endTime":"0","summary":"Singapore’s aspiring athletes now have more funding and support than ever before, says former national fencer and NMP Nicholas Fang.","market":"nz","thumbnail":"https://dam.mediacorp.sg/image/upload/s--E7uaF730--/c_fill,g_auto,h_468,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2024/08/19/kallang_1.jpg?itok=BAkBKUBm","type":0,"news_type":0,"thumbnails":["https://dam.mediacorp.sg/image/upload/s--E7uaF730--/c_fill,g_auto,h_468,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2024/08/19/kallang_1.jpg?itok=BAkBKUBm"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/commentary/singapore-sports-development-athletes-funding-support-kallang-5003791","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["BK4125","SSP","SSI"],"gpt_icon":0},{"id":"2519812397","title":"Hong Kong’s Fintech Ecosystem Expands as Blockchain, AI, and Digital Assets Take Center Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=2519812397","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519812397?lang=en_us&edition=fundamental","pubTime":"2025-03-15 17:54","pubTimestamp":1742032463,"startTime":"0","endTime":"0","summary":"Hong Kong’s fintech sector is experiencing rapid growth, with blockchain, digital assets, distributed ledger technology , and artificial intelligence  driving innovation.According to the latest Hong Kong Fintech Ecosystem report by InvestHK, the region now hosts over 1,100 fintech firms, including 175 blockchain-focused companies and 111 digital asset and cryptocurrency firms—marking a 250% and 30% increase, respectively, since 2022.The report also highlights that over 73% of fintech firms in Hong Kong focus on AI, significantly outpacing the 41.5% engaged in digital assets and cryptocurrency. Hong Kong’s unique advantage under China’s “one country, two systems” policy allows it to operate a free-market economy with unrestricted capital flow and strong international trade ties while maintaining close links to mainland China.Leveraging these strengths, the Hong Kong government has rolled out several Web3 innovations, including a licensing regime, spot Bitcoin and Ether exchange-traded f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/67d54e505fa75a693d35f015/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["SSI","FTVI"],"gpt_icon":0}],"pageSize":16,"totalPage":13,"pageCount":2,"totalSize":200}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SSI\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-11-21","symbol":"SSI","fiscalQuarterEnding":"2019/10","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1574312400000,"reportTimeType":"pre","actualEps":-0.15},{"date":"2019-08-22","symbol":"SSI","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2019/07","expectedEps":null,"defaultRemindTime":1566460800000,"name":null,"time":"Pre-Market","dateTimestamp":1566446400000,"actualEps":-0.6},{"market":"US","date":"2019-05-23","symbol":"SSI","fiscalQuarterEnding":"2019/04","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1558584000000,"reportTimeType":"pre","actualEps":-1.67},{"market":"US","date":"2019-03-07","symbol":"SSI","fiscalQuarterEnding":"2019/01","expectedEps":0.73,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1551934800000,"reportTimeType":"pre","actualEps":0.25},{"market":"US","date":"2018-12-03","symbol":"SSI","amount":0.05,"name":"Stage Stores Inc","currency":"USD","type":"dividend","dateTimestamp":1543813200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SSI\",market:\"US\",,,undefined,":[{"executeDate":"2017-02-24","recordDate":null,"paymentDate":null,"value":0.15,"currency":"USD"},{"executeDate":"2017-05-25","recordDate":null,"paymentDate":null,"value":0.05,"currency":"USD"},{"executeDate":"2017-08-25","recordDate":null,"paymentDate":null,"value":0.05,"currency":"USD"},{"executeDate":"2017-11-27","recordDate":null,"paymentDate":null,"value":0.05,"currency":"USD"},{"executeDate":"2018-03-05","recordDate":null,"paymentDate":null,"value":0.05,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SSI\",market:\"US\",delay:false,,,undefined,":{}}}